source
- STAT+: Three years of declining overdose deaths begets cautious optimism and some concernsThe next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning RoundsSTAT · 2mo ago↗ source
- Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacyHere we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at…Endpoints · 2mo ago↗ source
- STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage studyBiogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.STAT · 2mo ago